HIV

More than half of survey respondents with HIV reported concerns about possible drug-drug interactions.

Long-acting HIV medications could solve problems with adherence, reduce costly laboratory tests to monitor their efficacy, and bring down drug costs.

Top articles of the week from Specialty Pharmacy Times.

HIV patients lack crucial peroxisomal proteins in the brain.

Prequalification will allow countries to access generic sofosbuvir and an HIV self-test.

Response rate higher among patients with HIV treated with dolutegravir compared with lopinavir/ritonavir.

Top news of the day from across the health care landscape.

Dolutegravir-based treatment non-inferior to boosted protease inhibitor regimen in virally suppressed HIV-positive patients.

The future for pharmacy is very lucrative as they press on for provider status.

Resistance poses a global threat.

Fixed-dose combination tablet containing doravirine achieved viral suppression in HIV-1 infected treatment-naïve adults.

Immunization of cows induces rapid elicitation of broadly neutralizing antibodies to HIV.

Gilead's experimental combination therapy observed to reduce HIV RNA in adult patients.

Top news of the day from across the health care landscape.

The demand for innovation is not slowing down. 

Combination treatments well tolerated amongst study participants with HIV-1 infection.

Proper dosing of Vorinostat can help expose latent HIV.

New treatments for inflammatory conditions, cancer, and HIV are on the horizon. 

Top news of the day from across the health care landscape.

Enzyme acts as an epigenetic checkpoint of T cell function to treat cancer.

A look at the top stories in pharmacy last week.

Top articles of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.